8-K: Pliant Therapeutics Announces Positive Long-Term Data for Bexotegrast in Phase 2a PSC Trial

Pliant Therapeutics reported positive 24-week data from its Phase 2a trial of bexotegrast for primary sclerosing cholangitis (PSC), showing the drug was well-tolerated and demonstrated antifibrotic and anti-cholestatic activity.

Summary

• Pliant Therapeutics announced positive 24-week results from the 320 mg cohort of the INTEGRIS-PSC Phase 2a clinical trial for bexotegrast in patients with primary sclerosing cholangitis (PSC).
• The 320 mg treatment group met its primary endpoint, demonstrating that bexotegrast was well-tolerated up to 40 weeks of treatment.
• The trial also showed improvements in liver stiffness, alkaline phosphatase (ALP) levels, hepatocyte function, and bile flow compared to placebo.
• A reduction in Enhanced Liver Fibrosis (ELF) score was observed in patients at higher risk of disease progression.
• The study included 121 patients with PSC and suspected liver fibrosis, with 27 patients in the active arm and 9 in the placebo arm for the 320mg cohort.
• The FDA has provided feedback supporting a 52-week, dose-ranging Phase 2b trial using non-invasive endpoints.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results with strong safety and efficacy data, suggesting a high likelihood of success for the drug. The FDA feedback is also supportive, further boosting the positive sentiment.

Positives

• Bexotegrast demonstrated a favorable safety and tolerability profile.
• The drug showed broad antifibrotic activity in patients with PSC.
• There is potential for disease stabilization with bexotegrast treatment.
• The data supports the ongoing IPF development program centered on BEACON-IPF.
• The FDA is supportive of a 52-week, dose-ranging Phase 2b trial using non-invasive endpoints.

Negatives

• Interpretation of placebo findings at Week 24 was limited due to the small number of placebo participants (n=<2) enrolled in the MRI sub-study of the 320 mg cohort.

Risks

• The development and commercialization of product candidates are subject to risks, including delays in clinical trials.
• The company relies on third parties for critical aspects of development operations.
• There are risks inherent in the drug development process.
• The company may require additional financing.
• There are risks related to obtaining and maintaining intellectual property protection.

Future Outlook

Pliant will continue to evaluate the best path forward for the PSC program, with the FDA supporting a 52-week, dose-ranging Phase 2b trial using non-invasive endpoints.

Management Comments

• Eric Lefebvre, M.D., Chief Medical Officer of Pliant, stated that the data continues to highlight bexotegrast's favorable safety and tolerability profile and validates its broad antifibrotic activity.
• Gideon Hirschfield, FRCP, Ph.D., a principal investigator in the INTEGRIS-PSC trial, expressed encouragement by the consistent safety and efficacy trends and noted the strong clinical antifibrotic effect across multiple diseases.

Industry Context

This announcement is significant as there are currently no FDA or EMA-approved therapies for PSC, highlighting a high unmet need for new therapeutic options. The positive results for bexotegrast could position it as a potential treatment for this rare and progressive liver disease.

Comparison to Industry Standards

• The positive results of bexotegrast in reducing liver stiffness and improving ALP levels are encouraging when compared to the natural progression of PSC, where these markers typically worsen over time.
• While direct comparisons to other experimental PSC treatments are limited due to varying trial designs and endpoints, the observed improvements in liver function and fibrosis markers suggest a potentially competitive profile for bexotegrast.
• The use of transient elastography and MRI for assessing liver stiffness and function aligns with current best practices in evaluating PSC treatments, providing a robust dataset for analysis.

Stakeholder Impact

• Shareholders are likely to react positively to the encouraging clinical trial results.
• Patients with PSC may have a new potential treatment option.
• The positive data could lead to increased investor interest and potential partnerships.

Next Steps

• Pliant will continue to evaluate the best path forward for the PSC program.
• The company plans to evaluate a 52-week, dose-ranging Phase 2b trial employing non-invasive endpoints based on FDA feedback.

Key Dates

Keywords

bexotegrast, primary sclerosing cholangitis, PSC, liver fibrosis, antifibrotic, clinical trial, Phase 2a, INTEGRIS-PSC, alkaline phosphatase, ALP, liver stiffness, transient elastography, ELF score, hepatocyte function, bile flow